Disclosures for "Pharmacokinetics, Pharmacodynamics (PK/PD), and Safety Profile of Ulviprubart: Results from a 48-week, Open-label, Phase 1 Study in Patients with Inclusion Body Myositis (IBM)"
-
Dr. Needham has received personal compensation in the range of $500-$4,999 for serving as a Consultant for teva. Dr. Needham has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for abcuro. Dr. Needham has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for sanofi aventis.
-
Dr. Henderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Henderson has received publishing royalties from a publication relating to health care.
-
The institution of Dr. Liang has received research support from NHMRC Medical Research Future Fund. The institution of Dr. Liang has received research support from Abcuro for reimbursement of studies' costs.
-
Dr. Soler-Ferran has received personal compensation for serving as an employee of Abcuro. Dr. Soler-Ferran has stock in Pfizer.
-
Dr. Wilkins has received personal compensation for serving as an employee of Abcuro.
-
Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abcuro, Inc.. Dr. Greenberg has stock in Abcuro. Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care.